CKD Bio Corp. (KRX:063160)

Market Cap	130.57B
Revenue (ttm)	159.93B
Net Income (ttm)	-23.13B
Shares Out	5.49M
EPS (ttm)	-4,216.38
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.42%)
Ex-Dividend Date	Dec 27, 2024

Volume	20,931
Average Volume	21,660
Open	23,450
Previous Close	23,200
Day's Range	22,800 - 23,800
52-Week Range	19,710 - 32,150
Beta	1.23
RSI	54.69
Earnings Date	Aug 14, 2025

About CKD Bio

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 519
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 063160

Financial Performance

In 2022, CKD Bio's revenue was 156.04 billion, an increase of 9.70% compared to the previous year's 142.24 billion. Losses were -16.70 billion, 154.0% more than in 2021.